abstract |
A method of treating a RIP1 kinase-mediated disease or disorder, comprising administering to a patient in need of such treatment a RIP1 kinase-mediated disease or disorder, a compound that inhibits a therapeutically effective amount of RIP1 kinase and at least one other therapeutic active agent . |